Exelixis, Inc. - Common Stock (NQ:EXEL)

58.42 -0.02 (-0.03%)

Delayed Quote Updated: 11:22 AM EDT, Oct 8, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Exelixis, Inc. - Common Stock

< Previous 1 2

...

13 14 15 16 17 18 19 20 21

...

23 24 Next >

7 Biotech Stocks That Will Make You Rich in 10 Years ↗

January 18, 2023

Although the health innovation space is risky, the opportunities beckon a look at the biotech stocks that will make you rich in 10 years.

Via InvestorPlace

6 Analysts Have This to Say About Exelixis ↗

January 11, 2023

Via Benzinga

Exelixis Announces Preliminary Fourth Quarter and Full Year 2022 Financial Results, Provides 2023 Financial Guidance, and Outlines Key Priorities and Milestones for 2023

January 08, 2023

From Exelixis, Inc.

Via Business Wire

Four Undervalued Healthcare Stocks for 2023

January 06, 2023

These four health care stocks could be undervalued: Pfizer Inc., Regeneron Pharmaceuticals Inc., Innoviva Inc. and Exelixis Inc.

Via MarketBeat

Exelixis to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023 — Presentation to be webcast on www.exelixis.com —

January 03, 2023

From Exelixis, Inc.

Via Business Wire

Is Exelixis Stock a Buy Now? ↗

December 29, 2022

Don't be too quick to dismiss this company as a one-trick pony.

Via The Motley Fool

What 5 Analyst Ratings Have To Say About Exelixis ↗

December 09, 2022

Via Benzinga

2 Top Biotech Stocks to Buy for the Long Haul ↗

December 25, 2022

These mid-cap biotechs are solid long-term choices.

Via The Motley Fool

Exelixis Announces Initiation of the STELLAR-304 Phase 3 Pivotal Trial Evaluating Zanzalintinib in Patients with Advanced Non-Clear Cell Kidney Cancer

December 22, 2022

From Exelixis, Inc.

Via Business Wire

2 Beaten-Down Growth Stocks to Buy Before the Bull Run ↗

December 21, 2022

These could become hot buys once investors pivot back to growth stocks.

Via The Motley Fool

2 Biotech Stocks to Buy Hand Over Fist in 2023 and 1 to Avoid Like the Plague ↗

December 16, 2022

Two drug developers stand out as plain-as-day bargains in the new year, while another top-performing biotech stock looks poised to disappoint.

Via The Motley Fool

Nasdaq Bear Market: 5 Exceptionally Cheap Growth Stocks You'll Regret Not Buying on the Dip ↗

December 10, 2022

These bargain-basement-priced growth stocks are ripe for the picking following a 38% peak decline in the Nasdaq Composite.

Via The Motley Fool

Where Exelixis Stands With Analysts ↗

December 09, 2022

Via Benzinga

What 4 Analyst Ratings Have To Say About Exelixis ↗

November 02, 2022

Exelixis (NASDAQ:EXEL) has observed the following analyst ratings within the last quarter:

Via Benzinga

Exelixis' Cabometyx/Tecentriq Combo Misses Overall Survival Goal In Lung Cancer Setting ↗

December 09, 2022

Exelixis Inc (NASDAQ: EXEL) announced that the CONTACT-01 study

Via Benzinga

Exelixis Provides Update on Phase 3 CONTACT-01 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Metastatic Non-Small Cell Lung Cancer Previously Treated with Immunotherapy and Chemotherapy

December 08, 2022

From Exelixis, Inc.

Via Business Wire

Exelixis Announces Initial Dose-Escalation Results from the First-in-Human Phase 1 Trial Evaluating XL102 in Patients with Advanced Solid Tumors at SABCS 2022

December 08, 2022

From Exelixis, Inc.

Via Business Wire

Exelixis Inks Two Licensing Pacts For Cancer Programs ↗

November 02, 2022

Via Benzinga

Exelixis (EXEL) Q3 2022 Earnings Call Transcript ↗

November 02, 2022

EXEL earnings call for the period ending September 30, 2022.

Via The Motley Fool

3 Stocks to Buy Hand Over Fist in December ↗

December 03, 2022

These stocks could be big winners.

Via The Motley Fool

Exelixis to Present at the Virtual JMP Securities Hematology and Oncology Summit on December 7, 2022

November 30, 2022

From Exelixis, Inc.

Via Business Wire

Nasdaq Bear Market: 3 Surefire Growth Stocks to Buy to End the Year Right ↗

November 30, 2022

Investors can end the year on a high note by scooping up shares of these bargain-basement-priced growth stocks.

Via The Motley Fool

The Smartest Stocks to Buy With $20 Right Now ↗

November 16, 2022

You don't need a mountain of cash to begin building wealth on Wall Street.

Via The Motley Fool

2 No-Brainer Stocks to Buy Right Now for Less than $20 ↗

November 12, 2022

These stocks are still bargain-priced but benefit from long-term trends.

Via The Motley Fool

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in November

November 10, 2022

From Exelixis, Inc.

Via Business Wire

Here's Why This Growth Stock Is Already My 2022 Winner ↗

November 09, 2022

Despite a challenging year for the markets, this growth stock managed to stand out with another stellar quarter.

Via The Motley Fool

Looking Into Exelixis's Return On Invested Capital ↗

November 08, 2022

Pulled from Benzinga Pro data, Exelixis (NASDAQ:EXEL) posted Q3 earnings of $73.21 million, an increase from Q2 of 3.59%. Sales dropped to $411.74 million, a 1.83% decrease between quarters.

Via Benzinga

Exelixis and Catalent Enter into New License Agreement for Three Antibody-Drug Conjugate Programs with the Potential to Accelerate Exelixis’ Biologics Pipeline

November 03, 2022

From Exelixis, Inc.

Via Business Wire

Exelixis and Sairopa Establish Exclusive Clinical Development Collaboration and Option Agreement to Develop ADU-1805, a Potentially Best-in-Class Monoclonal Antibody Targeting SIRPα

November 01, 2022

From Exelixis, Inc.

Via Business Wire

Exelixis and Cybrexa Therapeutics Establish Exclusive Collaboration Providing Exelixis the Right to Acquire CBX-12, a Potential First-in-Class Peptide-Drug Conjugate of Exatecan

November 01, 2022

From Exelixis, Inc.

Via Business Wire

< Previous 1 2

...

13 14 15 16 17 18 19 20 21

...

23 24 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.